TRex Bio (NASDAQ:TRXB) Now Covered by Zacks Research

Zacks Research assumed coverage on shares of TRex Bio (NASDAQ:TRXB) in a research report released on Tuesday morning,Zacks reports. The firm issued a hold rating on the stock.

TRXB has been the subject of a number of other research reports. Wedbush assumed coverage on TRex Bio in a research note on Monday. They issued an “outperform” rating and a $30.00 price target for the company. Evercore began coverage on shares of TRex Bio in a research report on Tuesday. They set a “strong-buy” rating on the stock. Cantor Fitzgerald initiated coverage on shares of TRex Bio in a report on Tuesday. They issued an “overweight” rating for the company. JPMorgan Chase & Co. assumed coverage on shares of TRex Bio in a research report on Tuesday. They issued an “overweight” rating and a $20.00 target price for the company. Finally, Stifel Nicolaus initiated coverage on shares of TRex Bio in a research note on Tuesday. They set a “buy” rating and a $39.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, TRex Bio presently has a consensus rating of “Buy” and an average target price of $29.67.

TRex Bio Trading Down 1.3%

TRXB opened at $13.55 on Tuesday. TRex Bio has a 52-week low of $12.50 and a 52-week high of $16.56.

Insider Activity at TRex Bio

In other TRex Bio news, major shareholder Alexandria Venture Investments bought 178,571 shares of the company’s stock in a transaction dated Tuesday, October 13th. The shares were purchased at an average price of $14.00 per share, for a total transaction of $2,499,994.00. Following the acquisition, the insider owned 1,346,501 shares in the company, valued at approximately $18,851,014. This represents a 15.29% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

About TRex Bio

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.